Last reviewed · How we verify
AXS-07
AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief.
AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief. Used for Acute migraine with or without aura.
At a glance
| Generic name | AXS-07 |
|---|---|
| Sponsor | Axsome Therapeutics, Inc. |
| Drug class | Triptan combination / 5-HT1B/1D receptor agonist |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
The drug combines melitracen, which modulates monoamine reuptake and has analgesic properties, with rizatriptan, a selective 5-HT1B/1D receptor agonist (triptan). This combination is designed to provide faster onset and potentially greater efficacy than rizatriptan alone for acute migraine treatment. The melitracen component may enhance the triptan's effect through complementary mechanisms.
Approved indications
- Acute migraine with or without aura
Common side effects
- Dizziness
- Somnolence
- Nausea
- Chest discomfort
- Paresthesia
Key clinical trials
- Initiating Early Control of Migraine Pain and Associated Symptoms (PHASE3)
- Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) (PHASE3)
- Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) (PHASE3)
- Maximizing Outcomes in Treating Acute Migraine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AXS-07 CI brief — competitive landscape report
- AXS-07 updates RSS · CI watch RSS
- Axsome Therapeutics, Inc. portfolio CI